Shoot your shot... Johnson & Johnson reports earnings on Wednesday, but don't expect a major boost from vax sales: unlike Moderna and Pfizer, J&J pledged to sell its vaccine "at cost" (read: no profit). Out of $22B+ in sales last quarter, Covid vaccines made up just $100M of J&J's revenue — or roughly 2%. The no-profit approach could help J&J from a PR perspective. Not helpful: last week J&J recalled several Neutrogena and Aveeno spray sunscreens over a possible cancer risk, and it's dealing with lawsuits from its baby powder scandal.
Ghosted like a Fleet... Twitter and Snap kick off social media earnings on Thursday. In February, Snap got investors excited by saying it expects 50% annual sales growth for the next several years. Meanwhile, Twitter's yearly sales growth pales in comparison to Snap and Facebook's. It's been struggling to gain users, and it just killed its Stories feature "Fleets." More broadly, social media platforms continue to face criticism from regulators and customers for failing to police hate speech and misinformation. TBD if that'll hurt the bottom line.